balances three duties: protect participant welfare, steward evidence, and respect fairness across sites and countries.

Multiple models exist. A continued access program keeps eligible participants on therapy after the last trial visit while marketing applications proceed. A rollover extension study (often an open-label extension OLE or long-term extension LTE) collects longer-term safety and effectiveness, sometimes at community clinics to reflect real-world use. For individuals who are ineligible for an extension but face unmet medical need, pathways like expanded access (U.S.) and compassionate use (EU and other regions) may apply. In some countries, a named patient program NPP or other special access schemes (country-specific) allow physician-led requests. Finally, when approval and launch occur, teams must plan a transition to commercial supply, including an insurance coverage bridge and links to patient assistance programs so there is no treatment gap.

Ethically, these options sit under the umbrella of ethics of post-trial access: avoid harm from withdrawal, avoid false hope, and ensure fair criteria across geographies and subgroups (e.g., pediatric, rare disease). Practicality matters too—manufacturing capacity, stability dating, and pharmacovigilance responsibilities don’t disappear with the last patient out (LPO). That’s why the most resilient plans treat continuity as part of the clinical lifecycle rather than a scramble at study close.

Ground your program in authoritative expectations. Good Clinical Practice principles from the ICH frame participant protections and documentation. Patient-facing information and regulatory context are available from the FDA, the EMA, and the WHO; region-specific considerations can be found via Japan’s PMDA and Australia’s TGA. Your SOPs should echo these sources while translating policy into operational steps patients can actually use.

Plain communication is the first safeguard. Participants deserve clarity on whether an OLE/LTE is planned, who might qualify for a continued access program, and if physician-initiated routes like expanded access, compassionate use, or named patient program NPP could apply if the study ends before marketing approval. This is why informed consent for post-trial access belongs in the main consent, not as an afterthought—people can only plan their lives around care they understand.

Finally, continuity is more than drug supply. It includes a written continuity of care plan: handoffs to primary and specialty care, clear monitoring instructions, how to report side effects during and after access, and a phone number that still works after the last study visit. Without these basics, even a well-funded program can falter where patients need it most—between clinic, pharmacy, and home.

Designing the access pathway early: protocol language, eligibility, safety, and evidence

A reliable post-trial program starts before first-patient-in. Write a playbook at protocol level and align it across medical, clinical operations, regulatory, PV/quality, supply chain, legal, and payer/market access.

1) Protocol & consent language. State whether you plan an open-label extension OLE/long-term extension LTE, a continued access program, or both. Define high-level eligibility, expected duration, and the oversight model (investigator of record, community referrer, or hybrid). Include informed consent for post-trial access—plainly covering potential scenarios, criteria, and the reality that access can end if risk outweighs benefit or supply ends.

2) Eligibility & fairness. Draft objective medical criteria: clinical response thresholds, intolerance to alternatives, or risk of rebound on stopping. Avoid center-specific rules that create inequity. For global programs, specify how sites in different countries will handle physician-led channels (e.g., expanded access, compassionate use, special access schemes, named patient program NPP). Publish a decision tree and audit it—equity is a quality attribute.

3) Safety & pharmacovigilance. Map pharmacovigilance follow-up across all access types. Who captures adverse events? What counts as serious and unexpected? How do you maintain safety labs and pregnancy reporting? In extension studies, PV flows mirror trials; in physician-led access, you still own signal detection and reporting. Build a simple addendum for community clinicians so they know who to call and how to report.

4) Evidence & registries. When appropriate, pair access with a real-world evidence registry to observe long-term safety, durability, and patterns of use without over-burdening patients. Keep the “ask” minimal (e.g., PROs quarterly, annual labs pulled from records) and separate care from research participation to avoid coercion. Where registries aren’t feasible, retain minimal datasets necessary for safety and supply reconciliation.

5) Supply & quality. Treat extension and access supply like a micro-launch: stability budgeting, GMP release, temperature excursion workflows, and country-specific labeling. Decide whether you’ll ship to sites, specialty pharmacies, or direct-to-patient where lawful. Keep a wind-down plan that protects patients if a batch fails or a lot expires early.

6) Transitions & payers. From day one, sketch your insurance coverage bridge for when approval lands. Work with market access on prior-authorization templates, appeal letters, and specialty pharmacy onboarding. If coverage lags, activate patient assistance programs and transition rules so eligible patients don’t experience a gap between program end and reimbursement start. Communicate dates often and in writing.

7) Roles & training. Train investigators and coordinators on decision criteria, ordering, documentation, and emergency contacts. Create a one-page guide for primary care (shared care with PCP) that covers monitoring, drug interactions, vaccinations, and when to call the sponsor. Provide a 24/7 medical information line that persists after the last study visit.

From plan to patient: communication, logistics, and bridges to commercial supply

Execution succeeds on clarity and predictability. Begin counseling participants at least 3–6 months before LPO so they have time to make choices, book follow-ups, and prepare financially.

Clear patient communications. Issue a plain-language FAQ on all options (OLE/LTE, continued access program, physician-led routes like compassionate use, expanded access, special access schemes, and the pathway to commercial). Include practicals: visit cadence, costs, who orders labs, how to report AEs during access, and when access ends. Provide contact points that remain valid post-trial. For children and adolescents, write a youth-friendly version and involve caregivers in setting a continuity of care plan.

Site and pharmacy workflows. Decide who writes scripts, how refills are approved, and how drug accountability works outside the trial. If dispensing shifts to a specialty pharmacy, share a handoff template so patients understand authorizations, copays, and delivery windows. For home use, confirm storage, missed-dose instructions, and courier policies. This is where shared care with PCP matters—send a concise summary letter to the primary clinician with diagnosis, dose, monitoring, and red flags.

Financial bridges. Prepare multiple pathways: (1) a program that covers drug and essential labs during access; (2) an insurance coverage bridge with sample prior-auth wording; (3) links to patient assistance programs for those who qualify; and (4) a payer appeal kit. Map each to a timeline that starts before approval and ends after commercial onboarding to prevent gaps. When launch occurs, schedule outbound calls to help patients transition to transition to commercial supply smoothly.

Equity checks. Track who gets into OLE/LTE vs. who needs physician-led channels. Watch for disparities by site, language, rurality, or socioeconomic status. If participation diverges from the trial population, review your criteria and outreach materials. Add interpreters and travel support where they change outcomes. Equity is not a slogan—it’s a metric.

Aftercare & safety. Continue pharmacovigilance follow-up with simple reporting channels (phone, portal). Provide wallet cards noting drug name, dose, and sponsor contact for emergencies. For pregnancy exposures, have a streamlined intake pathway. If discontinuation is necessary, use taper plans and align with treating clinicians so patients are never left without guidance.

Rare disease and small populations. In ultra-rare settings, a formal OLE may be the only practical way to continue therapy and learn. When access depends on import via named patient program NPP or other special access schemes, build country-specific SOPs and patient letters. Keep expectations grounded and timelines transparent.

Governance that works: 90-day launch plan, metrics, and ready-to-use tools

Institutionalize continuity with a simple but strong governance rhythm. Use the following 90-day plan to stand up post-trial access before last-patient-last-visit.

1. Days 1–30: Decide & document. Confirm which models you will use: OLE/LTE, continued access program, physician-led routes (expanded access, compassionate use, named patient program NPP), and your insurance coverage bridge/patient assistance programs. Finalize protocol/consent wording (informed consent for post-trial access). Approve PV flows and supply plans. Align country differences with guidance from the FDA, EMA, PMDA, TGA, the ICH, and the WHO.
2. Days 31–60: Build & train. Publish the patient FAQ and HCP letters. Train sites on criteria, ordering, AE reporting, and pharmacy handoffs. Stand up a minimal real-world evidence registry (if appropriate) and the 24/7 medical info line. Test refill and shipping workflows, including temperature excursion responses. Record a 10-minute training for primary care (shared care with PCP).
3. Days 61–90: Launch & monitor. Open enrollment for OLE/LTE or the continued access program. Start physician-led requests where needed (special access schemes). Run equity and timeliness dashboards weekly. Kick off payer support: prior-auth templates, appeals, and bridge funding. Schedule transition calls for the first wave of transition to commercial supply when approval lands.

Measure what matters. Track time from last visit to first access dose; percentage of eligible patients onboarded; proportion bridged to commercial within 30/60/90 days; adverse event reporting timeliness; and equity by site/region/language. For PV, monitor expected vs. observed rates, and for supply, on-time-in-full metrics. Publish “we heard, we changed” notes if patients report friction.

Risk register—top pitfalls and fixes.

• Supply cliff at LPO. Fix: treat access like a mini-launch; reserve lots and build a wind-down plan.
• Opaque eligibility decisions. Fix: publish criteria and appeals; audit decisions across sites for fairness.
• Communication gaps post-trial. Fix: maintain an active phone/portal channel for 6–12 months beyond study end.
• Payer delays. Fix: activate insurance coverage bridge and patient assistance programs; push prior-auth templates to HCPs.
• Lost safety signals. Fix: simple pharmacovigilance follow-up scripts for patients and PCPs; quarterly check-ins.

Copy-paste templates.

Clinic letter for primary care (shared care with PCP):

Patient: [Name, DOB]
Study: [Title/ID] — Last visit: [Date]
Plan: Post-trial access via [OLE/LTE/Continued Access/Named Patient]. Dose: [X mg qd].
Monitoring: Labs [A/B] q[interval]; adverse event reporting to [phone/email].
Interactions/Precautions: [Key items].
Contact: 24/7 medical info [number]. Please call for any safety concerns or hospitalizations.

Patient FAQ excerpt:

• What are my options when the study ends? OLE/LTE, a continued access program, or physician-led requests (expanded access, compassionate use, special access schemes).
• Will I have costs? We’ll explain coverage and offer an insurance coverage bridge and patient assistance programs if needed.
• How is safety handled? We continue pharmacovigilance follow-up. Call [24/7 number] for side effects.
• How long does access last? Until commercial supply is available and you’re onboarded, or if risks outweigh benefits.

Keyword coverage checklist woven through this article: post-trial access; continued access program; compassionate use; expanded access; early access program; rollover extension study; long-term extension LTE; open-label extension OLE; named patient program NPP; transition to commercial supply; insurance coverage bridge; patient assistance programs; medication access after trial; continuity of care plan; shared care with PCP; pharmacovigilance follow-up; real-world evidence registry; informed consent for post-trial access; special access schemes; ethics of post-trial access.

Bottom line: continuity is a design choice, not a last-minute favor. Plan early, communicate plainly, measure equity, and bridge to commercial thoughtfully. Do this well and patients experience steady care, clean safety oversight, and a dignified handoff from research to real life.